Emerging Target-Based Paradigms to Prevent and Treat Migraine

Author: S D Silberstein
Source: Clinical Pharmacology & Therapeutics, 93: 78–85, 5 December 2012


Migraine is a primary brain disorder resulting from altered modulation of normal sensory stimuli and trigeminal nerve dysfunction. The second edition of the International Classification of Headache Disorders (ICHD-2) defines seven subtypes of migraine. Migraine treatment can be acute or preventive. New targeted therapies include 5-HT1F receptor agonists, calcitonin gene-related peptide (CGRP) antagonists, nitric oxide synthetase inhibitors, and ion channel antagonists. A recent development is the creation of antibodies to CGRP and its receptor for migraine prevention.
Download and read entire article at Clinical Pharmacology & Therapeutics.